Читать книгу 40 Years of Continuous Renal Replacement Therapy - Группа авторов - Страница 25

1Ronco C: Critical care nephrology: the journey has begun. Int J Artif Organs 2004;27:349–351.

2Ricci Z, Ronco C: Technical advances in renal replacement therapy. Semin Dial 2011;24:138–141.

3Lauer A, Saccaggi A, Ronco C, Belledonne M, Glabman S, Bosch JP: Continuous arteriovenous hemofiltration in the critically ill patient. Clinical use and operational characteristics. Ann Intern Med 1983;99:455–460.

4Ronco C, Garzotto F, Ricci Z: CA.R.PE.DI.E.M. (Cardio-Renal Pediatric Dialysis Emergency Machine): evolution of continuous renal replacement therapies in infants. A personal journey. Pediatr Nephrol 2012;27:1203–1211.

5Ronco C: Arterio-venous hemodiafiltration (A-V HDF): a possible way to increase urea removal during C.A.V.H. Int J Artif Organs 1985;8:61–62.

6Ronco C, Fabris A, Feriani M, et al: Technical and clinical evaluation of a new system for ultrafiltration control during hemodialysis. ASAIO Trans 1988;34:613–616.

7Ricci Z, Bonello M, Salvatori G, Ratanarat R, Brendolan A, Dan M, et al: Continuous renal replacement technology: from adaptive devices to flexible multipurpose machines. Crit Care Resusc 2004;6:180–187.

8Ronco C, Bellomo R: The evolving technology for continuous renal replacement therapy from current standards to high volume hemofiltration. Curr Opin Crit Care 1997;3:426–433.

9Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356:26–30.

10Ricci Z, Salvatori G, Bonello M, et al: A new machine for continuous renal replacement therapy: from development to clinical testing. Expert Rev Med Devices 2005;2:47–55.

11Garzotto F, Ostermann M, Martín-Langerwerf D, Sánchez-Sánchez M, Teng J, Robert R, Marinho A, Herrera-Gutierrez ME, Mao HJ, Benavente D, Kipnis E, Lorenzin A, Marcelli D, Tetta C, Ronco C; DoReMIFA Study Group: The dose response multicentre investigation on fluid assessment (DoReMIFA) in critically ill patients. Crit Care 2016;20:196.

12Lorenzin A, Garzotto F, Alghisi A, Neri M, Galeano D, Aresu S, Pani A, Vidal E, Ricci Z, Murer L, Goldstein SL, Ronco C: CVVHD treatment with CARPEDIEM: small solute clearance at different blood and dialysate flows with three different surface area filter configurations. Pediatr Nephrol 2016;31:1659–1665.

13Villa G, Ricci Z, Romagnoli S, Ronco C: Multidimensional approach to adequacy of renal replacement therapy in acute kidney injury; in Ding X, Ronco C (eds): Acute Kidney Injury From Diagnosis to Care.

Contrib Nephrol. Basel, Karger, 2016, vol 187, pp 94–105.

14Nalesso F, Giuliani A, Basso F, Brendolan A, Ronco C: [Timing and dose in renal replacement therapy]. Cir Cir 2013;81:177–180.

15Ricci Z, Ronco C: Renal replacement therapy in the critically ill: getting it right. Curr Opin Crit Care 2012;18:607–612.

16Ricci Z, Ronco C: Timing, dose and mode of dialysis in acute kidney injury. Curr Opin Crit Care 2011;17:556–561.

17Vesconi S, Cruz DN, Fumagalli R, Kindgen-Milles D, Monti G, Marinho A, Mariano F, Formica M, Marchesi M, René R, Livigni S, Ronco C; Dose Response Multicentre International Collaborative Initiative (DO-RE-MI Study Group): Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit Care 2009;13:R57.

18Ronco C, Cruz D, Oudemans van Straaten H, Honore P, House A, Bin D, Gibney N: Dialysis dose in acute kidney injury: no time for therapeutic nihilism – a critical appraisal of the acute renal failure trial network study. Crit Care 2008;12:308.

19Ricci Z, Bellomo R, Ronco C: Dose of dialysis in acute renal failure. Clin J Am Soc Nephrol 2006;1:380–388.

20Monti G, Herrera M, Kindgen-Milles D, Marinho A, Cruz D, Mariano F, Gigliola G, Moretti E, Alessandri E, Robert R, Ronco C: The dose response multicentre international collaborative initiative (DO-RE-MI); in Ronco C, Bellomo R, Kellum JA (eds): Acute Kidney Injury. Contrib Nephrol. Basel, Karger, 2007, vol 156, pp 434–443.

21Reiter K, Bellomo R, Ronco C, Kellum JA: Pro/con clinical debate: is high-volume hemofiltration beneficial in the treatment of septic shock? Crit Care 2002;6:18–21.

22Ronco C, Bonello M, Bordoni V, Ricci Z, D’Intini V, Bellomo R, Levin NW: Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 2004;22:164–174.

23Piccinni P, Dan M, Barbacini S, Carraro R, Lieta E, Marafon S, Zamperetti N, Brendolan A, D’Intini V, Tetta C, et al: Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006;32:80–86.

24Reiter K, D’Intini V, Bordoni V, Baldwin I, Bellomo R, Tetta C, Brendolan A, Ronco C: High-volume hemofiltration in sepsis. Nephron 2002;92:251–258.

25Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, d’Intini V, Bellomo R: Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792–801.

26Mariano F, Fonsato V, Lanfranco G, Pohlmeier R, Ronco C, Triolo G, Camussi G, Tetta C, Passlick-Deetjen J: Tailoring high-cutoff membranes and feasible application in sepsis-associated acute renal failure: in vitro studies. Nephrol Dial Transplant 2005;20:1116–1126.

27Ronco C, Brendolan A, D’Intini V, Ricci Z, Wratten ML, Bellomo R: Coupled plasma filtration adsorption: rationale, technical development and early clinical experience. Blood Purif 2003;21:409–416.

28Ronco C, Bellomo R: Acute renal failure and multiple organ dysfunction in the ICU: from renal replacement therapy (RRT) to multiple organ support therapy (MOST). Int J Artif Organs 2002;25:733–747.

29Ronco C: The place of early haemoperfusion with polymyxin B fibre column in the treatment of sepsis. Crit Care 2005;9:631–633.

30Cruz DN, de Cal M, Piccinni P, Ronco C: Polymyxin-B hemoperfusion and endotoxin removal: lessons from a review of the literature; in Ronco C, Piccinni P, Rosner MH (eds): Endotoxemia and Endotoxin Shock. Contrib Nephrol. Basel, Karger, 2010, vol 167, pp 77–82.

31Kellum JA, Ronco C: The 17th acute disease quality initiative international consensus conference: introducing precision renal replacement therapy. Blood Purif 2016;42:221–223.

32Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, et al: Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care 2016;20:318.

33Villa G, Neri M, Bellomo R, Cerda J, De Gaudio AR, De Rosa S, Garzotto F, Honore PM, Kellum J, Lorenzin A, Payen D, Ricci Z, Samoni S, Vincent JL, Wendon J, Zaccaria M, Ronco C; Nomenclature Standardization Initiative (NSI) Alliance: Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care 2016;20:283.

34Ronco C: The Charta of Vicenza. Blood Purif 2015;40:1–5.

35Ronco C, La Manna G: Current Perspectives in Kidney Diseases. Blood Purif 2017;44:311–313.

36Yamashita A, Masaki H, Kobayashi E, Sukegawa T: Evaluation of solute penetration across the polysulfone membrane with vitamin E coating. Hemodial Int 2015;19(suppl 3):S2–-S25.

37Ronco C, Brendolan A, Bragantini L, et al: Treatment of acute renal failure in newborns by continuous arterio-venous hemofiltration. Kidney Int 1986;29:908–915.

38Ronco C, Garzotto F, Brendolan A, Zanella M, Bellettato M, Vedovato S, Chiarenza F, Ricci Z, Goldstein SL: Continuous renal replacement therapy in neonates and small infants: development and first-in-human use of a miniaturised machine (CARPEDIEM). Lancet 2014;383:1807–1813.

39Cerdá J, Baldwin I, Honore PM, Villa G, Kellum JA, Ronco C; ADQI Consensus Group: Role of technology for the management of AKI in critically ill patients: from adoptive technology to precision continuous renal replacement therapy. Blood Purif 2016;42:248–265.

40Cianciolo G, Colí L, La Manna G, Donati G, D’Addio F, Comai G, Ricci D, Dormi A, Wratten M, Feliciangeli G, Stefoni S: Is beta2-microglobulin-related amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach. Int J Artif Organs 2007;30:864–878.

41Colì L, Donati G, Cappuccilli ML, Cianciolo G, Comai G, Cuna V, Carretta E, La Manna G, Stefoni S: Role of the hemodialysis vascular access type in inflammation status and monocyte activation. Int J Artif Organs 2011;34:481–488.

42La Manna G, Ghinatti G, Tazzari PL, Alviano F, Ricci F, Capelli I, Cuna V, Todeschini P, Brunocilla E, Pagliaro P, Bonsi L, Stefoni S: Neutrophil gelatinase-associated lipocalin increases HLA-G(+)/FoxP3(+) T-regulatory cell population in an in vitro model of PBMC. PLoS One 2014;9:e89497.

43Camussi G, Ronco C, Montrucchio G, Piccoli G: Role of soluble mediators in sepsis and renal failure. Kidney Int Suppl 1998;66:S3–-S42.

44Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Straaten HO, Ronco C, Kellum JA: Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study. Crit Care Med 2009;37:2576–2582.

45Cruz DN, Perazella MA, Bellomo R, Corradi V, de Cal M, Kuang D, Ocampo C, Nalesso F, Ronco C: Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 2006;48:361–371.

Claudio Ronco, MD

Department of Nephrology Dialysis and Transplantation International Renal

Research Institute of Vicenza (IRRIV) St. Bortolo Hospital

Viale Rodolfi 37

IT–36100 Vicenza (Italy)

E-Mail cronco@goldnet.it

This article has already been published in: Contrib Nephrol. Basel, Karger, 2017, vol 189, pp 114–123. Reproduced here with permission from the publisher.